TEVA(US:TEVA) Globenewswire·2025-05-31 01:05Core Insights - Teva Pharmaceuticals has highlighted a significant gap in the diagnosis and treatment of tardive dyskinesia (TD) among patients in long-term care (LTC) facilities, emphasizing the need for improved awareness and understanding of this condition [1][2][3] Study Findings - The study analyzed a database of approximately 700,000 residents on antipsychotic drugs (APDs) and about 35,000 on metoclopramide (Reglan), revealing that mood disorders were the most common underlying psychiatric diagnoses, affecting 68% and 54% of residents respectively [2][7] - More than half of the residents with TD in LTC settings do not receive standard care treatment, and one-quarter remain untreated, indicating a critical need for better diagnostic practices [6][7] - Among residents treated with APDs, only 1.1% had a specific diagnosis of TD, while 5.6% were diagnosed with extrapyramidal syndrome (EPS), which can lead to inappropriate treatment options [7] Implications for Care - The findings suggest that many individuals with TD in LTC facilities are at risk of not receiving appropriate diagnoses or standard care, necessitating more intensive evaluations to improve treatment accuracy [3][6] - Less than half of the patients diagnosed with TD received the recommended standard of care treatment, primarily a vesicular monoamine transporter 2 inhibitor (VMAT2i), with many being treated with non-FDA approved options [7]